Is Halozyme Therapeutics, Inc. (HALO) a Buy, Sell, or Hold?
NASDAQ : HALO
Halozyme Therapeutics, Inc.
$83.445 USD
$1.97 (2.41%)
- Volume
- 2.62M
- Average Volume
- 1.81M
- Market Capitalization
- $9.9B
- P/E Ratio
- 28.58
- Dividend Yield
- 0.00%
- Price Target
- $91.50
- Year High
- $84.44
- Year Low
- $58.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.76
Company Overview
NASDAQ
Helen I. Torley
Biotechnology
Healthcare
HALO
423
US
USD
Liquidity Metrics
9.76
2.76
2.33
0.85
0.00
Sales & Valuation
$1.4B
6.56
44.89
14.82
5.65
Profitability
$2.56
$316.89M
23.13%
33.37%
126.27%
13.05%
P/E Metrics
28.58
-1.18
-1.18
Analyst Price Target & Rating
$91.50
$95.00
$75.00
3/5
27 Analysts
-8.80%
Financial Health Scores
3.98
6/9
$639.83M
$2.67B
$2.45B
$522.48M
Key Metrics (TTM)
$11.5B
7.62
18.43
2.76
126.27%
23.65%
3.62%
6.91%
$11.11
259 days
Company Executives
| Name | Title |
|---|---|
| Rhys de Callier | Chief Strategy Officer |
| Charles Theuer | Chief Medical Officer |
| Christopher Wahl | Chief Scientific Officer |
| Helen I. Torley | President, Chief Executive Officer & Director |
| Chase Coffman | President of Hypercon |
| Darren Snellgrove | Senior Vice President & Chief Financial Officer |
| David A. Ramsay | President of Drug Delivery |
| Mark Snyder | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary |
| Cortney Caudill | Senior Vice President & Chief Operating Officer |
| Tram Bui | Head of Investor Relations & Corporate Communications |
| Paul Spence | Chief Commercial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It als ... o plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Halozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High – Here’s What Happened
2026-07-26 02:02:01
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) shares reached a new 52-week high on Friday. The company traded as high as $82.99 and last traded at $81.5140, with a volume of 217609 shares trading hands. The stock had previously closed at $80.84. Analyst Ratings Changes HALO has been the topic of several analyst
Halozyme to Report Second Quarter 2026 Financial and Operating Results
2026-07-23 08:30:00
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading. Halozyme will host a conference call on Thursday, August 6, 2026 at 1:30pm PT/4:30pm ET to discuss the results.
Halozyme's Partnerships, Earnings Growth See Shares Near All-Time Highs
2026-07-22 07:21:25
Halozyme Therapeutics, Inc. (HALO) shares gain 539% since first Big Money outlier inflow signal in March 2014.
HALO Inks Deal With INCY to Support Cancer Therapy Development
2026-07-21 11:40:31
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
2026-07-20 08:00:00
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focus on the potential for ENHANZE® to strengthen the subcutaneous formulation currently in development for INCA033989, with the goal of enabling more convenient delivery and dosing regimens that may improve the treatment experience.
Fifth Third Bancorp Grows Position in Halozyme Therapeutics, Inc. $HALO
2026-07-19 04:05:38
Fifth Third Bancorp increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 4,206.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,128 shares of the biopharmaceutical company's stock after acquiring an additional 66,546 shares during the quarter. Fifth Third Bancorp
Inflation Cools But US-Iran Tensions Rise: 4 Value Stocks to Buy Now
2026-07-16 11:36:10
ARCO, HALO, TX and ARRY screen as high-earnings-yield value picks as the Middle-East conflict sharpens stock selection.
2026-07-16 10:37:07
HALO stocks are gaining favor as investors rotate toward tangible assets and AI-resistant businesses. Here are ETFs to play the trend.
Frequently Asked Questions
-
What is the current Halozyme Therapeutics, Inc. (HALO) stock price?
-
Halozyme Therapeutics, Inc.(NASDAQ:HALO) stock price is $83.445 in the last trading session. During the trading session, HALO stock reached the peak price of $84.44 while $58.53 was the lowest point it dropped to. The percentage change in HALO stock occurred in the recent session was 2.41% while the dollar amount for the price change in HALO stock was $1.97.
-
HALO's industry and sector of operation?
-
The NASDAQ listed HALO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HALO?
-
Rhys de Callier | Chief Strategy Officer
Charles Theuer | Chief Medical Officer
Christopher Wahl | Chief Scientific Officer
Helen I. Torley | President, Chief Executive Officer & Director
Chase Coffman | President of Hypercon -
How many employees does HALO have?
-
Number of HALO employees currently stands at 423. HALO operates from 12390 El Camino Real, San Diego, CA 92121, US.
-
Link for HALO official website?
-
Official Website of HALO is: https://www.halozyme.com
-
How do I contact HALO?
-
HALO could be contacted at phone #858 794 8889 and can also be accessed through its website. HALO operates from 12390 El Camino Real, San Diego, CA 92121, US.
-
How many shares of HALO are traded daily?
-
The average number of HALO shares traded daily for last 3 months was 1.81M.
-
What is the market cap of HALO currently?
-
The market value of HALO currently stands at $9.9B with its latest stock price at $83.445